Clinical pipeline Minerva Biotechnologies is a clinical stage biopharmaceutical company accelerating a CAR-T and immunotherapy pipeline, presenting a sales opportunity to collaborate on development, manufacturing, and regulatory support for solid tumor and metastatic cancer therapies.

MUC1*.Target advantage Their lead CAR-T program huMNC2-CAR44 targets the MUC1* growth factor receptor, with a metastatic breast cancer addressable market where up to 95% express MUC1*, suggesting potential partnerships in biomarker-driven trials, companion diagnostics, and patient stratification services.

Partnership history Past collaborations include a license agreement with Memorial Sloan Kettering and leadership moves to business development, indicating openness to licensing, co-development, and strategic alliances with academic centers and pharma.

Expansion momentum The company states ongoing expansion to include a second CAR-T product focused on persistence, plus next-gen therapies and small molecule approaches, signaling opportunities for collaboration across platform capabilities, contract research, and scalable manufacturing.

Funding & growth With revenue in the low tens of millions and total funding around seventy million, Minerva shows early-stage growth potential and a need for strategic commercial, manufacturing, or distribution partnerships to scale its therapies and accelerate market entry.